Patents Examined by Noble E Jarrell
  • Patent number: 12005046
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: June 11, 2024
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffrey Claude Pelletier, Garry Robert Smith, Haiyan Bian
  • Patent number: 12005047
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Grant
    Filed: July 29, 2023
    Date of Patent: June 11, 2024
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian
  • Patent number: 12006311
    Abstract: The present invention relates to compounds of formula (I) for use in preventing and/or treating cancer.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: June 11, 2024
    Assignees: FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRONINSTITUT DE RECERCA, INSTITUT UNIV. DE CIÈNCIA I TECNOLOGIA, S. A.
    Inventors: Josep Roma Castanyer, Marta Pascual Gilabert, José Sánchez De Toledo Codina, Soledad Gallego Melcón, Patricia Zarzosa Martínez, Javier Alonso Fernández, Sergio Pérez Ozcáriz, Cristina López Gómez, Josep Castells Boliart
  • Patent number: 11999701
    Abstract: A 4,5-bis(4-chlorophenyl)-2-phenyl-1H-imidazole compound, its synthesis, and its use as an anticancer, anti-inflammatory, and/or antimicrobial agent.
    Type: Grant
    Filed: October 23, 2023
    Date of Patent: June 4, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Amer A. Amer, Antar Ahmed Abdelhamid Ahmed
  • Patent number: 11998610
    Abstract: Disclosed are conjugates including a recognition element covalently bonded to or linked through a linker to a payload. The payload is a pharmaceutical agent (e.g., an antineoplastic agent, anti-infective agent, or anti-inflammatory agent) or a diagnostic agent. Also disclosed are methods of using the conjugates.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: June 4, 2024
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Spencer Cory Peck, Steven John Taylor, Elijah Lane Bogart, Devin Forest Reed Doud, Joo Hyun Im, Dervla Tamara Isaac, Jenny Liu, Ferdinand Edward Massari, Robert Walter Myers, John Robert Proudfoot, Cheri Ross, John Patrick Casey, Jr., David Arthur Berry
  • Patent number: 11999718
    Abstract: The Present invention provides a novel pyrazole derivative compound represented by Chemical formula 1, a stereoisomer thereof, a solvate thereof, an isotopic variant thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. (In the above, A, B and R, and the like are the same as defined in the description of the invention.
    Type: Grant
    Filed: January 6, 2023
    Date of Patent: June 4, 2024
    Assignee: APTABIO THERAPEUTICS INC.
    Inventors: Soo Jin Lee, Sung Hwan Moon, Sooho Ban, Eunsil Lee, Eun Jung Shin, Yoo-Kyung Goh
  • Patent number: 11993573
    Abstract: Chemical compounds that inhibit cancer cell growth are provided. The compounds are heteroarotinoids and derivatives thereof with oxygen, nitrogen or sulfur in chroman systems, tetrahydroquinoline systems, and tetrahydrothiochroman systems.
    Type: Grant
    Filed: February 4, 2021
    Date of Patent: May 28, 2024
    Assignee: THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY
    Inventors: Kenneth Darrell Berlin, Richard A. Bunce, Krishna Kumar Gnanasekaran, Field M. Watts, Jr., Donghua Howard Zhou
  • Patent number: 11993603
    Abstract: A medicament with excellent JAK kinase (Janus Kinase) inhibitory activity can be used to prevent, treat and/or improve an autoimmune disease (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus and the like). The present invention also provides a pharmaceutically acceptable composition containing the compound and a method for preparing these compounds.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: May 28, 2024
    Assignees: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES & PEKING UNION MEDICAL COLLEGE, CHINA PARMACEUTICAL UNIVERSITY
    Inventors: Tiantai Zhang, Dayong Zhang, Chengjuan Chen, Yuan Yin, Runan Yu, Lei Shu
  • Patent number: 11980597
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Grant
    Filed: March 30, 2023
    Date of Patent: May 14, 2024
    Assignee: Duke University
    Inventors: Kaitlyn Andreano, Ching-yi Chang, Donald P. McDonnell, Stephanie L. Gaillard
  • Patent number: 11970478
    Abstract: A 9-(2-hydroxyquinolin-3-yl)-10-(2-hydroxyethyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahydroacridine1,8(2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: November 16, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11970492
    Abstract: The present invention provides 11-arylcinnolino[2,3-f]phenanthridinium salt compounds and method for producing the same by highly regioselective synthesis of 11-phenylimino[2,3-f]phenanthridin-9-ium salts from 2-azobiaryls and alkenes under catalysis of palladium, through double oxidative C—H coupling of alkenes, to give the polycyclic cinnolinophenanthridinium salts in moderate yields. The reaction mechanism involves ortho C—H olefination of 2-azobiaryls by alkenes, intramolecular aza-Michael addition, ?-hydride elimination, electrophilic palladation followed by intramolecular C—H activation and reductive elimination. The prepared quaternary ammonium salts are candidate materials for solution-processable OLED and bioimaging materials.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: April 30, 2024
    Assignee: NATIONAL CHIAO TUNG UNIVERSITY
    Inventors: Shih-Ching Chuang, Jayakumar Jayachandran
  • Patent number: 11970494
    Abstract: The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.
    Type: Grant
    Filed: November 8, 2022
    Date of Patent: April 30, 2024
    Assignee: Ajax Therapeutics, Inc.
    Inventors: Craig E. Masse, Jeremy R. Greenwood, Jiayi Xu, Sayan Mondal, Phani Ghanakota
  • Patent number: 11964949
    Abstract: The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: April 23, 2024
    Assignee: The Global Alliance for TB Drug Development, Inc.
    Inventors: Christopher B. Cooper, Haihong Huang, Dongfeng Zhang, Nader Fotouhi, Takushi Kaneko
  • Patent number: 11958855
    Abstract: The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: April 16, 2024
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Todd B. Sells, Stephen G. Stroud
  • Patent number: 11958810
    Abstract: Preparation of optionally substituted dihydroisoquinolines. The present invention relates to a process for the preparation of optionally substituted dihydroi-soquinolines of the formula I.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: April 16, 2024
    Assignee: BASF SE
    Inventors: Bernd Mueller, Michael Rack, Michael Seet, Ana Escribano Cuesta, Jan Klaas Lohmann, Georg Christoph Rudolf, Markus Nett, Rainer Hoffmann
  • Patent number: 11944605
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: April 2, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Eddine Saiah, David John O'Neill, Seong Woo Anthony Kang
  • Patent number: 11939432
    Abstract: Synthetic amino acid-modified polymers and methods of making the same and using the same are disclosed. The synthetic amino acid-modified polymers possess distinct thermosensitive, improved water-erosion resistant, and enhanced mechanical properties, and are suitable of reducing or preventing formation of postoperative tissue adhesions. Additionally, the amino acid-modified polymers can also be used as a vector to deliver pharmaceutically active agents.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: March 26, 2024
    Assignee: PROVIEW-MBD BIOTECH CO., LTD.
    Inventors: Yu-Chia Chang, Yunn-Kuen Chang, Wen-Yen Huang, Ging-Ho Hsiue, Hsieh-Chih Tsai, Shuian-Yin Lin, Nai-Sheng Hsu, Tzu-Yu Lin
  • Patent number: 11932623
    Abstract: A compound represented by the following formula (A) has excellent control efficacy against weeds, and shows high safety against useful plants.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: March 19, 2024
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Toshiyuki Kiji
  • Patent number: 11926599
    Abstract: A 1-(2-chlorobenzylideneamino)-5,5-diphenylimidazolidine-2,4-dione compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 23, 2023
    Date of Patent: March 12, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11918589
    Abstract: A medicament for preventive and/or therapeutic treatment of multiple sclerosis, especially a pain accompanying multiple sclerosis such as neuropathic pain, which contains a compound having a P2X4 receptor antagonist activity such as a compound represented by the general formula (IH), or a salt thereof or a hydrate or solvate thereof as an active ingredient.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: March 5, 2024
    Assignees: NIPPON CHEMIPHAR CO., LTD., KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
    Inventors: Toshiyasu Imai, Toru Kawasaki, Toru Ogawa, Kazuhide Inoue